Genocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Meeting 2021
Pro-tumor effects detected as early as four days after Inhibigen administration Insights into Inhibigen biology may yield new therapeutic targets...
Staff
OncXerna Therapeutics Provides New Results from its Xerna™ RNA-based Biomarker Platform at the AACR Annual Meeting
Xerna™ TME Panel describes the tumor microenvironment based on dominant biology subtypes with prognostic capabilities in colorectal cancer Data supports...
NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021
BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting
LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell...
Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021
SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing...
iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021
Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid...
Gennao Bio Presents New Data on Novel Gene Monoclonal Antibody Platform Technology at the American Association for Cancer Research (AACR) 2021 Annual Meeting
~ Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a cell penetrating antibody, to non-covalently...
MacroGenics Announces Presentations at the 2021 AACR Annual Meeting
ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative...
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition Pan-cancer anti-tumor activity, including in tumors...
Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting
Proprietary TurboCAR Technology Platform Allows Cytokine Activation Signaling to be Selectively Engineered into AlloCAR T™ CellsNew TurboCAR Constructs Can Be Induced...
Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass. and NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology...
Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001
Bolt’s first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC) currently in an ongoing Phase...
Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021
KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1 Interferon pathways resulting in superior...
Valneva Announces Publication of 2020 Universal Registration Document and Provides Business Updates
Saint-Herblain (France), April 10, 2021 – Valneva SE (“Valneva” or the "Company”), a specialty vaccine company focused on the development...
Valneva Files Registration Statement for Proposed United States Initial Public Offering
Saint-Herblain (France), April 10, 2021 – Valneva SE (the “Company”), a specialty vaccine company focused on the development and commercialization...
National Research Corporation Declares Quarterly Dividend
Lincoln, Nebraska, April 09, 2021 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRC) announced that its Board of Directors has declared...
Biogen Announces Two New Nominees for Election to Board of Directors
Nominees bring diverse business and public health experience key to Biogen’s mission to pioneer and lead in neuroscienceCompany thanks Director...
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Company Announcement FDA action date is Oct 10, 2021BLA submission supported by positive pivotal innovaTV 204 trial results presented at...
Scilex Holding, a Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for ZTlido® Label Expansion
PALO ALTO, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics...
Convocation annual general meeting and extraordinary general shareholders meeting
Regulated informationNazareth (Belgium)/Rotterdam (Netherlands), 9 April 2021 Convocation annual general meeting and extraordinary general shareholders meeting The board of directors...